In the present study, first cycle treatment with G-CSF and the modified regimen without fluorouracil through bolus intravenous infusion curtailed neutropenia, which enabled patients in the FOLFIRINOX group to continue the therapy. The gene discussed is CSF3; the disease is Decreased total neutrophil count.